Meeting
2024 ASCO Annual Meeting
Phase I trial of chidamide, an oral HDAC inhibitor, in combination with oral etoposide in patients with refractory/recurrent neuroblastoma.
Authors
Feifei Sun
Sun Yat-sen University Cancer Center, Guangzhou, China
Feifei Sun , Zijun Zhen , Suying Lu , Jia Zhu , Juan Wang , Junting Huang , Yi Que , Yizhuo Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT05338541
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10034)
DOI
10.1200/JCO.2024.42.16_suppl.10034
Abstract #
10034
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I study of proteasome inhibitor bortezomib in combination with irinotecan in patients with relapsed/refractory neuroblatoma.
First Author: Rajen Mody
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2023 ASCO Annual Meeting
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
First Author: Chia-Chi Lin